Bahija Jallal Net Worth

The estimated Net Worth of Bahija Jallal is at least $649 mil dollars as of 15 June 2022. Bahija Jallal owns over 1,814 units of Guardant Health Inc stock worth over $184,237 and over the last 7 years he sold GH stock worth over $0. In addition, he makes $464,522 as Independent Director at Guardant Health Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Bahija Jallal GH stock SEC Form 4 insiders trading

Bahija has made over 1 trades of the Guardant Health Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 1,814 units of GH stock worth $45,114 on 15 June 2022.

The largest trade he's ever made was exercising 1,814 units of Guardant Health Inc stock on 15 June 2022 worth over $45,114. On average, Bahija trades about 181 units every 0 days since 2018. As of 15 June 2022 he still owns at least 7,408 units of Guardant Health Inc stock.

You can see the complete history of Bahija Jallal stock trades at the bottom of the page.

Bahija Jallal biography

Dr. Bahija Jallal Ph.D. serves as Independent Director of the Company. Prior to that, Dr. Jallal served as Executive Vice President of AstraZeneca PLC, a pharmaceutical and biopharmaceutical company, from October 2013 to January 2019, and President of MedImmune, a subsidiary of AstraZeneca, from January 2013 to January 2019. She joined MedImmune in 2006 and held various research and development positions, including Senior Vice President, Research and Development, from 2010 to 2013. She received her Ph.D. degree in physiology and DEA degree in physiology and biology from the Université de Paris VI, and her AEA degree in plant physiology and M.S. degree in biology from the Université de Paris VII.

What is the salary of Bahija Jallal?

As the Independent Director of Guardant Health Inc, the total compensation of Bahija Jallal at Guardant Health Inc is $464,522. There are 7 executives at Guardant Health Inc getting paid more, with Michael Wiley having the highest compensation of $2,216,070.

How old is Bahija Jallal?

Bahija Jallal is 58, he's been the Independent Director of Guardant Health Inc since 2019. There are 5 older and 10 younger executives at Guardant Health Inc. The oldest executive at Guardant Health Inc is Stanley Meresman, 73, who is the Independent Director.

What's Bahija Jallal's mailing address?

Bahija's mailing address filed with the SEC is 505, Penobscot Drive, Redwood City, San Mateo County, California, 94063, United States.

Insiders trading at Guardant Health Inc

Over the last 6 years, insiders at Guardant Health Inc have traded over $2,653,630,540 worth of Guardant Health Inc stock and bought 2,438,210 units worth $45,173,576 . The most active insiders traders include Bluebird (Cayman) Ltd Softb..., Bluebird (Cayman) Ltd Svf E..., eHelmy Eltoukhy. On average, Guardant Health Inc executives and independent directors trade stock every 6 days with the average trade being worth of $2,415,822. The most recent stock trade was executed by Kumud Kalia on 9 September 2024, trading 6,545 units of GH stock currently worth $162,774.

What does Guardant Health Inc do?

we believe conquering cancer is a big data problem. that’s why we built the world’s leading comprehensive liquid biopsy. this non-invasive tool for accessing and sequencing tumor dna is used by thousands of oncologists to help tens of thousands of advanced cancer patients. we believe the boom in cancer data acquisition we helped launch will drive important discoveries and new products. we’re working on some exciting ones, including in early detection, where the impact on patients can be profound. we’ve raised more than $500 million from investors including sequoia capital, khosla ventures, orbimed, and softbank.

Complete history of Bahija Jallal stock trades at Anthem Inc e Guardant Health Inc

Guardant Health Inc executives and stock owners

Guardant Health Inc executives and other stock owners filed with the SEC include:

• Michael Wiley,
  Chief Legal Officer
• Derek Bertocci,
  Chief Financial Officer
• Helmy Eltoukhy,
  Chief Executive Officer, Director
• AmirAli Talasaz,
  Chairman of the Board, President, Chief Operating Officer
• John G. Saia,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Michael J. Wiley,
  Head of Corp. Affairs
• Dr. Richard B. Lanman,
  Advisor
• Bahija Jallal,
  Independent Director
• Ian Clark,
  Lead Independent Director
• Stanley Meresman,
  Independent Director
• Samir Kaul,
  Independent Director
• Dr. AmirAli Talasaz Ph.D.,
  Co-CEO & Director
• Dr. Helmy Eltoukhy Ph.D.,
  Co-Founder, Co-CEO & Chairman
• Lynn Lewis,
  IR Contact Officer
• Vijaya Gadde,
  Director
• Kumud Kalia,
  Chief Information Officer
• Dr. Richard B. Lanman M.D.,
  Advisor
• Steven Collora,
  VP of Sales
• Daniel Simon,
  Sr. VP of Biopharma Bus. Devel.
• Andy Ament,
  Sr. VP of Operations
• Mark Jacobstein,
  Chief User Engagement Officer
• Amelia Merrill,
  VP of People
• Michael Bell,
  Chief Financial Officer
• Richard B. Lanman,
  Chief Medical Officer
• Terilyn J. Monroe,
  Chief People Officer
• Musa Tariq,
  Director
• Craig Eagle,
  Chief Medical Officer
• Meghan V. Joyce,
  Director
• Group Capital Ltd Softbank ...,
  
• Us (Ttgp), Ltd.Sc U.S. Vent...,
  
• Vision Fund (Aiv M1) L.P.Sb...,
  
• Beta Pte. Ltd.Temasek Life ...,
  
• Advisors Llc Orbimed,
  10% owner
• Ultimate General Partner Se...,
  
• Ventures Iv, L.P.Khosla Ven...,
  
• Ultimate General Partner X,...,
  
• Bluebird (Cayman) Ltd Softb...,
  
• Dipchand Nishar,
  Director
• Aaref Hilaly,
  Director
• John G. Saia,
  Chief Legal Officer
• Bluebird (Cayman) Ltd Svf E...,
  
• Chris Freeman,
  Chief Commercial Officer
• Myrtle S Potter,
  Director
• Steve E. Krognes,
  Director
• Michael Brian Bell,
  Chief Financial Officer
• Amelia Merrill,
  SVP, People
• Medina Manuel Hidalgo,
  Director
• Darya Chudova,
  Chief Technology Officer
• Ines Dahne Steuber,
  Chief Operating Officer